Recent Advances of Receptor Tyrosine Kinases in Solid Tumors
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: closed (30 April 2025) | Viewed by 15916
Special Issue Editor
Special Issue Information
Dear Colleagues,
This Special Issue, "Recent Advances of Receptor Tyrosine Kinases in Solid Tumors", will mainly focus on the role of new therapies targeting Receptor Tyrosine Kinases and their downstream signaling in solid tumors.
Receptor tyrosine kinases (RTKs) are a large family of receptors with similar structures. RTKs are crucial targets for treating cancer. Since 2000, when the first tyrosine kinase inhibitor (TKI), imatinib, was approved to target multiple RTKs, three generations of TKIs have been developed. They have been involved in significant progress in the personalized treatment of cancer during the past twenty years. TKIs are approved for several solid tumors, especially against epidermal growth factor receptors (EGFR) in patients with non-small cell lung cancer (NSCLC) and against HER2 in metastatic and Her2-positive breast cancer. However, acquired resistance and the lack of response to TKIs are important challenges for the patients treated with these drugs. TKIs, combined with other targeted therapies, chemotherapy, or immunotherapy, have been recommended to address these issues. Furthermore, advanced therapeutic tools such as bispecific antibodies (e.g., against EGFR/c-MET for NSCLC; against PD-L1/c-MET for HCC) and antibody–drug conjugates (e.g., against ALK for neuroblastoma), as well as chimeric antigen receptor (CAR) T cell and CAR natural killer (NK) cell therapies targeting c-MET in gastric cancer and lung adenocarcinoma, have been recently developed in cancer research as perspective therapies for the RTK-targeted treatment of tumors.
I invite authors to submit original research and review articles focusing on the biological functions and therapeutic potential, highlighting the future direction of RTK signaling in solid tumors.
Dr. Parham Jabbarzadeh Kaboli
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- targeted-therapy
- solid tumors
- receptor tyrosine kinase
- tyrosine kinase inhibitor
- FDA
- c-MET
- VEGFR
- EGFR
- ALK
- growth factor
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.